Caring for patients with multiple myeloma?
Consider the LINKER studies
What is the LINKER-MM3 clinical research study?
Clinicaltrials.gov Clinicaltrialsregister.eu
With limited treatment options and no cure for multiple myeloma (MM), the LINKER clinical research studies are currently underway to evaluate the safety, tolerability and efficacy of an investigational drug. Consider the LINKER studies as an opportunity for your patients with MM to access emerging treatments.
The investigational drug is administered as an IV infusion given between once a week and once a month. It is a bispecific antibody that binds to BCMA, a protein found at a higher rate on cancerous plasma cells, and to CD3 on T-cells. The study drug is called “investigational” as it has not yet been approved for use outside of this study.
The length of participation will depend on several factors, including the participant’s response to treatment. Participants may be able to remain in the study until their MM progresses and will be asked to attend study visits once a week to once a month.
Participants will be reimbursed for reasonable costs related to their participation in the LINKER studies, such as travel and food costs. Participants will be reimbursed for travel to and from study visits. Medical care related to their participation, including the study drug, will be provided at no cost.

The investigational drug is
administered as an IV
infusion

An IV infusion given
between once a week and
once a month

The length of participation
will depend on several
factors

Learn More

How can you help?

The LINKER studies are enrolling a total of over 400 people worldwide with MM. The success of the LINKER studies depends on physicians to refer potential study participants. If you have potentially eligible and interested patients, empower them with options and discuss the LINKER studies with them. You may also contact the nearest study site to refer them.
Learn more >
Site Finder
Clinicaltrials.gov
Clinicaltrialsregister.eu
The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented in clinical research by talking to them about the LINKER studies.
Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with MM.